IP Library Granted Patent US 7,208,527
Granted Patent B2
US 7,208,527 · App. 10/496,859 · Granted Apr 24, 2007

Potassium channel modulators

Assignee: Poseidon Pharmaceuticals A/S
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,208,527
App. No.
10/496,859
Granted
Apr 24, 2007
Kind
B2
Abstract

This invention relates to novel compounds useful as potassium channel modulators. More specifically the invention provides chemical compounds useful as modulators of SK Ca and/or IK Ca channels.

Claims (32)

1. A compound according to Formula I

or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein

L 1 , L 2 , and L 3 are absent;

X and Y both represent a phenyl group, which phenyl group is substituted with halogen;

Z represents alkyl, alkenyl, alkynyl, or cycloalkyl; and

D represents —CN, R 6 —CN, or —CON(R 2 R 3 ), wherein

R 2 and R 3 , independently of each another, represent hydrogen or alkyl; and

R 6 represents alkyl.

2. The compound of claim 1 , which is

2-(2-Fluoro-phenyl)-2-(4-fluoro-phenyl)-pent-4-enenitrile;

2-(2-Fluoro-phenyl)-2-(4-fluoro-phenyl)-3-methyl-butyronitrile;

2,2-Bis-(4-fluoro-phenyl)-3-methyl-butyronitrile;

2,2-Bis-(4-fluoro-phenyl)-4-methyl-pentanenitrile;

2,2-Bis-(4-fluoro-phenyl)-pent-4-enenitrile;

2,2-Bis-(4-fluoro-phenyl)-pent-4-ynenitrile;

2-(2-Fluoro-phenyl)-2-(4-fluoro-phenyl)-pent-4-ynenitrile;

2-(2-Fluoro-phenyl)-2-(4-fluoro-phenyl)-4-methyl-pentanenitrile;

2-(3-Fluoro-phenyl)-2-(4-fluoro-phenyl)-3-methyl-butyronitrile;

2-(3-Fluoro-phenyl)-2-(4-fluoro-phenyl)-4-methyl-pentanenitrile;

2-(3-Fluoro-phenyl)-2-(4-fluoro-phenyl)-pent-4-enenitrile;

2-(3-Fluoro-phenyl)-2-(4-fluoro-phenyl)-pent-4-ynenitrile; or

2,2-Bis-(4-fluoro-phenyl)-3-methyl-butyramide;

or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.

4. The compound of claim 1 , wherein X and Y both represent a phenyl group substituted with fluoro or chloro.

5. The compound of claim 1 , wherein X and Y both represent a phenyl group substituted with fluoro.

6. The compound of claim 1 , wherein Z represents alkyl.

7. The compound of claim 1 , wherein D represents —CN.

8. The compound of claim 1 , wherein D represents —CON(R 2 R 3 ), wherein R 2 and R 3 , independently of each another, represent hydrogen or alkyl.

9. The compound of claim 1 , wherein D represents —CON(R 2 R 3 ), wherein R 2 and R 3 hydrogen.

10. The compound of claim 1 , which is 2,2-Bis-(4-fluoro-phenyl)-3-methyl-butyronitrile, or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , which is 2,2-Bis-(4-fluoro-phenyl)-3-methyl-butyramide, or a pharmaceutically acceptable salt thereof.

Assignments (5)
CHANGE OF ADDRESS OF ASSIGNEE Recorded Oct 21, 2020
From: SANIONA A/S
To: SANIONA A/S
Reel/Frame 054396/0996 →
CHANGE OF NAME Recorded Oct 24, 2018
From: ANIONA APS
To: SANIONA A/S
Reel/Frame 047299/0383 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2013
From: NEUROSEARCH A/S
To: ANIONA APS
Reel/Frame 030049/0894 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2008
From: POSEIDON PHARMACEUTICALS A/S
To: NEUROSEARCH A/S
Reel/Frame 021050/0961 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2004
From: GOULIAEV, ALEX HAAHR; SLOK, FRANK ABILDGAARD; TEUBER, LENE; DEMNITZ, JOACHIM
To: POSEIDON PHARMACEUTICALS A/S
Reel/Frame 015560/0257 →
Priority Claims (1)
DK 2002 00013 · Jan 4, 2002 · national
Continuity (1)
Related Publication 20050009816A1 · Jan 13, 2005